Abstract
Vertex is collaborating with Aventis Pharma AG (formerly Hoechst Marion Roussel Inc) in the development of pralnacasan, an interleukin (IL)-1b converting enzyme (ICE) inhibitor, for the potential treatment of inflammatory diseases [170247], [188293], [453094].
Publication types
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
Anti-Inflammatory Agents, Non-Steroidal* / chemistry
-
Anti-Inflammatory Agents, Non-Steroidal* / pharmacology
-
Anti-Inflammatory Agents, Non-Steroidal* / therapeutic use
-
Azepines* / chemistry
-
Azepines* / pharmacology
-
Azepines* / therapeutic use
-
Caspase Inhibitors
-
Clinical Trials, Phase I as Topic
-
Clinical Trials, Phase II as Topic
-
Humans
-
Isoquinolines* / chemistry
-
Isoquinolines* / pharmacology
-
Isoquinolines* / therapeutic use
-
Protease Inhibitors* / chemistry
-
Protease Inhibitors* / pharmacology
-
Protease Inhibitors* / therapeutic use
-
Pyridazines* / chemistry
-
Pyridazines* / pharmacology
-
Pyridazines* / therapeutic use
-
Structure-Activity Relationship
-
Treatment Outcome
Substances
-
Anti-Inflammatory Agents, Non-Steroidal
-
Azepines
-
Caspase Inhibitors
-
Isoquinolines
-
Protease Inhibitors
-
Pyridazines
-
pralnacasan